Doctor On Demand said the move improves access to high-quality, convenient healthcare for beneficiaries across all 50 states.
Through Doctor On Demand, beneficiaries are able to connect with a board-certified physician of their choice over secure live video from home, 24 hours a day, 7 days a week.
Doctor On Demand is the first nationwide, full-service telehealth provider to expand its medical services to include Medicare Part B coverage following the Centers for Medicare and Medicaid Services expansion of telehealth services in response to the COVID-19 outbreak.
The Medicare Part B population consists largely of Americans over the age of 65, many of whom are considered at heightened risk during the pandemic.
Beneficiaries can access consistent medical care for 90 % of the most common conditions treated by both primary care and urgent care facilities, including diagnosis and testing of COVID-19; typical ailments like infections, rashes, cold and flu; ongoing care of chronic disease like asthma and COPD, diabetes, high blood pressure, high cholesterol and thyroid issues; and for prescription refills.
Patients can see the same physician time and time again, building a trusted, personal relationship via video.
Prior to CMS's expansion of telemedicine to those with Medicare Part B coverage, Doctor On Demand had already seen rapid adoption of its virtual care services within this demographic, with patient registrations for the 65 and over age group growing by nearly 150 % in March.
Doctor On Demand can be accessed through a smartphone, tablet or computer by downloading the Doctor On Demand app from the App Store or Google Play, or from a web browser.
To register, beneficiaries enter a valid email address, Medicare ID number, and a phone number.
During the COVID-19 public health emergency, Doctor On Demand is waiving the copay for Medicare Part B beneficiaries, as permitted by government policy.
The company is headquartered in San Francisco with offices in Minneapolis and Washington, DC.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies